Abstract:The VEGF (vascular endothelial growth factor) pathway has emerged as an important target for cancer therapy, with VEGF signaling pathway (VSP) inhibitors having been approved for several different malignancies. Less anticipated has been the multitude of cardiovascular and renal effects of these therapies. Hypertension occurs in at least a quarter of patients starting VSP inhibitors, with virtually every patient having an absolute increase in blood pressure. Patients can also develop proteinuria, renal dysfunction, vascular events, or cardiomyopathy. Although these toxicities have been generally manageable, they have introduced cardiovascular and renal considerations for patient care. On the other hand, these sequelae have provided a growing appreciation for the critical role of VEGF in vascular and renal homeostasis in human biology. Although several recent articles have addressed practical considerations with respect to patient care with this class of drugs,1–4 this review will explore mechanisms associated with the vascular toxicities arising from VEGF signaling inhibition in cancer treatment. The human VEGF family consists of 5 related glycoproteins: VEGFA, VEGFB, VEGFC, VEGFD, and PIGF (placental growth factor). These are secreted to form homodimers, which interact with a family of 3 receptor tyrosine kinases: VEGFR1 (VEGF receptor 1), VEGFR2, and VEGFR3 (Figure 1). VEGFA and VEGFB bind to VEGFR1, VEGFA binds to VEGFR2, and VEGFC and VEGFD bind to both VEGFR2 and VEGFR3.1,5 PIGF primarily interacts with VEGFR1. The VEGFRs are found on a wide variety of cell types. VEGFR1, also called Flt-1 (fms-like tyrosine kinase 1), is found on vascular endothelial cells, hematopoietic stem cells, monocytes, and macrophages. VEGFR2, also called KDR (kinase insert domain) or Flk-1 (fetal liver kinase 1), is expressed on vascular and lymphatic endothelial cells; VEGFR3 (also called Flt-4) is restricted to lymphatic endothelial cells.5 On ligand binding, VEGFRs transduce intracellular signals through …

Vascular endothelial growth factor family of ligands and receptors: review

The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions

A Structural Overview of Vascular Endothelial Growth Factors Pharmacological Ligands: From Macromolecules to Designed Peptidomimetics

Biology and therapeutic targeting of vascular endothelial growth factor A

Vascular Endothelial Growth Factor and Atherosclerosis

The biology of VEGF and its receptors

VEGF in biological control

VEGF receptor protein-tyrosine kinases: structure and regulation

Molecular and functional diversity of vascular endothelial growth factors

VEGFR1 signaling in retinal angiogenesis and microinflammation

Vascular endothelial growth factor (VEGF), VEGF receptors and their inhibitors for antiangiogenic tumor therapy

Vascular endothelial growth factor (VEGF) - key factor in normal and pathological angiogenesis

Mechanisms of VEGF (Vascular Endothelial Growth Factor) Inhibitor–Associated Hypertension and Vascular Disease

VEGFA and tumour angiogenesis

Structure and Function of Vascular Endothelial Growth Factor and Its Related Proteins

Vascular endothelial growth factor signaling in development and disease

Advances of Research on Vascular Endothelial Growth Factor Receptors in Epidermal Neoplasm

VEGF in Signaling and Disease: Beyond Discovery and Development

Vascular endothelial growth factor-D: signaling mechanisms, biology, and clinical relevance

VEGFA, B, C: Implications of the C-Terminal Sequence Variations for the Interaction with Neuropilins

The Vascular Endothelial Growth Factor Family and Antiangiogesis Therapy